Malinka Jansson

2.3k total citations · 1 hit paper
11 papers, 742 citations indexed

About

Malinka Jansson is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Malinka Jansson has authored 11 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Malinka Jansson's work include Cancer Immunotherapy and Biomarkers (10 papers), Radiomics and Machine Learning in Medical Imaging (3 papers) and CAR-T cell therapy research (3 papers). Malinka Jansson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Radiomics and Machine Learning in Medical Imaging (3 papers) and CAR-T cell therapy research (3 papers). Malinka Jansson collaborates with scholars based in United States. Malinka Jansson's co-authors include Kenneth Emancipator, Karina Kulangara, Ellie Corigliano, Nancy R. Zhang, Grant Toland, Marisa Dolled‐Filhart, Charlotte Roach, Debra Hanks, Supriya Shah and Jared Lunceford and has published in prestigious journals such as Journal of Clinical Oncology, Archives of Pathology & Laboratory Medicine and Applied immunohistochemistry & molecular morphology.

In The Last Decade

Malinka Jansson

11 papers receiving 733 citations

Hit Papers

Clinical Utility of the Combined Positive Score for Progr... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
    2018 378 citations Karina Kulangara, Nancy R. Zhang et al. Archives of Pathology & Laboratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Malinka Jansson United States 4 639 350 170 125 103 11 742
Ellie Corigliano United States 3 546 0.9× 307 0.9× 146 0.9× 109 0.9× 80 0.8× 4 635
Debra Hanks United States 5 404 0.6× 206 0.6× 155 0.9× 81 0.6× 65 0.6× 10 510
Rita P. Dalal United States 10 415 0.6× 311 0.9× 144 0.8× 109 0.9× 88 0.9× 21 622
Jiangdian Wang United States 8 671 1.1× 409 1.2× 273 1.6× 174 1.4× 77 0.7× 11 860
Charlotte Roach United States 10 608 1.0× 357 1.0× 101 0.6× 152 1.2× 99 1.0× 15 717
Marta Martín-Richard Spain 17 483 0.8× 238 0.7× 190 1.1× 60 0.5× 148 1.4× 42 708
Holly Kemberling United States 7 471 0.7× 154 0.4× 125 0.7× 99 0.8× 118 1.1× 9 567
Daniel J. Boffa United States 10 279 0.4× 372 1.1× 318 1.9× 68 0.5× 250 2.4× 21 693
Ashley Kowalewski United States 5 677 1.1× 331 0.9× 66 0.4× 225 1.8× 140 1.4× 5 768
Marina Pulido France 10 315 0.5× 275 0.8× 48 0.3× 134 1.1× 84 0.8× 25 522

Countries citing papers authored by Malinka Jansson

Since Specialization
Citations

This map shows the geographic impact of Malinka Jansson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malinka Jansson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malinka Jansson more than expected).

Fields of papers citing papers by Malinka Jansson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malinka Jansson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malinka Jansson. The network helps show where Malinka Jansson may publish in the future.

Co-authorship network of co-authors of Malinka Jansson

This figure shows the co-authorship network connecting the top 25 collaborators of Malinka Jansson. A scholar is included among the top collaborators of Malinka Jansson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malinka Jansson. Malinka Jansson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Jansson, Malinka, et al.. (2023). PD-L1 IHC 22C3 pharmDx Demonstrates Precision and Reproducibility in Triple-negative Breast Cancer. 7(1). 1–9. 1 indexed citations
2.
Polewski, Monika D., Malinka Jansson, Kenneth Emancipator, et al.. (2021). Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Head and Neck Squamous Cell Carcinoma. 5(1). 9–17. 2 indexed citations
3.
Kulangara, Karina, et al.. (2020). PD-L1 IHC 22C3 pharmdx demonstrates precision and reproducibility in detecting PD-L1 expression in triple negative breast cancer.. Journal of Clinical Oncology. 38(15_suppl). e13104–e13104. 3 indexed citations
4.
Kulangara, Karina, Nancy R. Zhang, Ellie Corigliano, et al.. (2018). Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Archives of Pathology & Laboratory Medicine. 143(3). 330–337. 378 indexed citations breakdown →
5.
Phillips, Thérèse, Xiaoling Zhang, Malinka Jansson, et al.. (2017). Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. Applied immunohistochemistry & molecular morphology. 26(1). 6–12. 17 indexed citations
6.
William, Josette, Debra Hanks, Malinka Jansson, et al.. (2017). Development of a diagnostic PD-L1 immunohistochemical assay for nivolumab therapy in urothelial carcinoma.. Journal of Clinical Oncology. 35(15_suppl). e14585–e14585. 1 indexed citations
7.
Álvarez, Sara, Debra Hanks, Josette William, et al.. (2017). Assay performance of the PD-L1 IHC 28-8 pharmDx assay in squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 35(15_suppl). e14588–e14588. 2 indexed citations
8.
Álvarez, Sara, Josette William, Debra Hanks, et al.. (2017). Development of a clinical trial immunohistochemistry (IHC) assay using a novel antibody to CD38.. Journal of Clinical Oncology. 35(15_suppl). 7561–7561. 1 indexed citations
9.
Roach, Charlotte, Nancy R. Zhang, Ellie Corigliano, et al.. (2016). Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer. Applied immunohistochemistry & molecular morphology. 24(6). 392–397. 249 indexed citations
10.
Dolled‐Filhart, Marisa, Charlotte Roach, Grant Toland, et al.. (2016). Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. Archives of Pathology & Laboratory Medicine. 140(11). 1243–1249. 86 indexed citations
11.
Dolled‐Filhart, Marisa, Scot Ebbinghaus, Charlotte Roach, et al.. (2016). Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma.. Journal of Clinical Oncology. 34(15_suppl). 9571–9571. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellie Corigliano Breakdown of academic impact, for papers by Debra Hanks Breakdown of academic impact, for papers by Rita P. Dalal Breakdown of academic impact, for papers by Jiangdian Wang Breakdown of academic impact, for papers by Charlotte Roach Breakdown of academic impact, for papers by Marta Martín-Richard Breakdown of academic impact, for papers by Holly Kemberling Breakdown of academic impact, for papers by Daniel J. Boffa Breakdown of academic impact, for papers by Ashley Kowalewski Breakdown of academic impact, for papers by Marina Pulido
Rankless by CCL
2026